A Pilot Survey: Oral Function as One of the Risk Factors for Physical Frailty

Background: The aim of this study was to examine the association of the multiple facets of oral, motor, and social functions in community-dwelling older adults, to identify factors that might influence the risk of frailty. Methods: Of the 82 participants included in the study, 39 (5 males and 34 females) were young-old adults, with an average age of 70.5 ± 2.8 years, and 43 (14 males and 29 females) were old-old adults, with an average age of 78.7 ± 2.9 years. We assessed the risk factors for frailty among oral, motor, and social functions. Results: Statistical analysis showed a significant difference in the oral diadochokinesis between the groups (p = 0.006). According to the Spearman correlation analysis, a significant association was observed with age and oral diadochokinesis (rs = −0.262, p = 0.018), and social support (rs = −0.219, p = 0.049). Moreover, binomial logistic regression analysis revealed a significant association of frailty with the occlusal force (odds ratio, 0.031; 95% confidence interval (95% CI), 0.002–0.430; p = 0.010), General Oral Health Index (odds ratio, 0.930; 95% CI, 0.867–0.999, p = 0.046), and availability of social support (odds ratio, 0.803, 95% CI, 0.690–0.934, p = 0.004). Conclusions: To prevent frailty at an early stage, assessments of oral functions, and also that of the availability of social support, are important

Bending and torsional properties of commercial nickel-titanium orthodontic wires

The aim of this study was to investigate the force delivery for a variety of types and sizes of commercially available nickel-titanium wires. The relationship of the magnitude of the force and the tooth displacement in a severe crowding case is discussed. Nine brands of nickel-titanium orthodontic wires in a variety of sizes were examined with a three-point bending test and a torsion test at 37℃. Most wires exhibited superelastic behavior for the three-point bending and torsion tests at 37℃. In the three-point bending test, the variation of the average load at 1.5mm deflection during unloading ranged from 0kgf for Copper Ni-Ti 40℃ with a 0.016×0.022 inch cross-section to 0.46kgf for ORTHO LINE with a 0.021×0.025 inch cross-section. The average torsion load at a rotation of 30°on deactivation varied from 0kgf-cm for Copper Ni-Ti 40℃ to 0.023kgf-cm for ORTHO LINE. The predicted torsional angles for the maxillary arch in the severe crowding case were smaller than expected and only three positions exceeded 20°. Considering the play between bracket slots and archwire, nickel-titanium orthodontic wires of the superelastic type may not exhibit superelastic properties for torsion in most clinical situations

Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi-center, open-label, 52-week phase 3 trial

Intravenous immunoglobulin (IVIg) therapy is currently the only established treatment in patients with multifocal motor neuropathy (MMN), and many patients have an IVIg‐dependent fluctuation. We aimed to investigate the efficacy and safety of every 3 week IVIg (1.0 g/kg) for 52 weeks. This study was an open‐label phase 3 clinical trial, enrolling 13 MMN patients. After an induction IVIg therapy (0.4 g/kg/d for 5 consecutive days), maintenance dose (1.0 g/kg) was given every 3 weeks for 52 weeks. The major outcome measures were the Medical Research Council (MRC) sum score and hand‐grip strength at week 52. This trial is registered with ClinicalTrials.gov, number NCT01827072. At week 52, 11 of the 13 patients completed the study, and all 11 had a sustained improvement. The mean (SD) MRC sum score was 85.6 (8.7) at the baseline, and 90.6 (12.8) at week 52. The mean grip strength was 39.2 (30.0) kPa at the baseline and 45.2 (32.8) kPa at week 52. Two patients dropped out because of adverse event (dysphagia) and decision of an investigator, respectively. Three patients developed coronary spasm, dysphagia, or inguinal herniation, reported as the serious adverse events, but considered not related with the study drug. The other adverse effects were mild and resolved by the end of the study period. Our results show that maintenance treatment with 1.0 g/kg IVIg every 3 week is safe and efficacious for MMN patients up to 52 weeks. Further studies are required to investigate optimal dose and duration of maintenance IVIg for MMN